ACE2/Ang 1-7 axis: A critical regulator of epicardial adipose tissue inflammation and cardiac dysfunction in obesity

Adipocyte

Volumn 5, Issue 3, 2016, Pages 306-311

  Patel, Vaibhav B ^a   Basu, Ratnadeep ^a   Oudit, Gavin Y ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiotensin 1 7; Angiotensin converting enzyme 2; epicardial adipose tissue; obesity; renin angiotensin system

Indexed keywords

ADIPONECTIN; ANGIOTENSINOGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR;

DOWN REGULATION; EPICARDIAL FAT; HEART DISEASE; HEART FAILURE; HEART MUSCLE METABOLISM; HUMAN; INSULIN RESISTANCE; MACROPHAGE; NOTE; OBESITY; PROTEIN EXPRESSION; SOFT TISSUE INFLAMMATION; UPREGULATION;

EID: 85031689841     PISSN: 21623945     EISSN: 2162397X     Source Type: Journal    
DOI: 10.1080/21623945.2015.1131881     Document Type: Note

References (38)

1. S.Kenchaiah, H.D.Sesso, J.M.Gaziano. Body mass index and vigorous physical activity and the risk of heart failure among men. Circulation 2009; 119:44-52; PMID:19103991; http://dx.doi.org/10.1161/CIRCULATIONAHA.108.807289.
2. S.Kenchaiah, J.C.Evans, D.Levy, P.W.Wilson, E.J.Benjamin, M.G.Larson, W.B.Kannel, R.S.Vasan. Obesity and the risk of heart failure. N Engl J Med 2002; 347:305-13; PMID:12151467; http://dx.doi.org/10.1056/NEJMoa020245.
3. T.E.Owan, D.O.Hodge, R.M.Herges, S.J.Jacobsen, V.L.Roger, M.M.Redfield. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355:251-9; PMID:16855265; http://dx.doi.org/10.1056/NEJMoa052256.
4. C.W.Yancy, M.Jessup, B.Bozkurt, J.Butler, D.E.Casey, Jr., M.H.Drazner, G.C.Fonarow, S.A.Geraci, T.Horwich, J.L.Januzzi, et al. 2013 ACCF/AHA guideline for the management of heart failure:executive summary:a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:1810-52; PMID:23741057; http://dx.doi.org/10.1161/CIR.0b013e31829e8807.
5. G.Iacobellis. Epicardial and pericardial fat:close, but very different. Obesity 2009; 17:625; author reply 6–7; PMID:19322142; http://dx.doi.org/10.1038/oby.2008.575.
6. B.Gaborit, N.Venteclef, P.Ancel, V.Pelloux, V.Gariboldi, P.Leprince, J.Amour, S.N.Hatem, E.Jouve, A.Dutour, et al. Human epicardial adipose tissue has a specific transcriptomic signature depending on its anatomical peri-atrial, peri-ventricular, or peri-coronary location. Cardiovasc Res 2015; 108:62-73; PMID:26239655; http://dx.doi.org/10.1093/cvr/cvv208.
7. C.Doesch, D.Haghi, S.Fluchter, T.Suselbeck, S.O.Schoenberg, H.Michaely, M.Borggrefe, T.Papavassiliu. Epicardial adipose tissue in patients with heart failure. J Cardiovasc Magn Reson 2010; 12:40; PMID:20624277; http://dx.doi.org/10.1186/1532-429X-12-40.
8. K.Watanabe, T.Kishino, J.Sano, T.Ariga, S.Okuyama, H.Mori, S.Matsushima, K.Ohtsuka, H.Ohnishi, T.Watanabe. Relationship between epicardial adipose tissue thickness and early impairment of left ventricular systolic function in patients with preserved ejection fraction. Heart Vessels 2015. http://dx.doi.org/10.1007/s00380-015-0650-8.
9. S.R.Tipnis, N.M.Hooper, R.Hyde, E.Karran, G.Christie, A.J.Turner. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275:33238-43; PMID:10924499; http://dx.doi.org/10.1074/jbc.M002615200.
10. M.Donoghue, F.Hsieh, E.Baronas, K.Godbout, M.Gosselin, N.Stagliano, M.Donovan, B.Woolf, K.Robison, R.Jeyaseelan, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 2000; 87:E1-9; PMID:10969042; http://dx.doi.org/10.1161/01.RES.87.5.e1.
11. M.Bader, N.Alenina, M.A.Andrade-Navarro, R.A.Santos. MAS and its related G protein-coupled receptors, Mrgprs. Pharmacol Rev 2014; 66:1080-105; PMID:25244929; http://dx.doi.org/10.1124/pr.113.008136.
12. S.Engeli, P.Schling, K.Gorzelniak, M.Boschmann, J.Janke, G.Ailhaud, M.Teboul, F.Massiéra, A.M.Sharma. The adipose-tissue renin-angiotensin-aldosterone system:role in the metabolic syndrome? Int J Biochem Cell Biol 2003; 35:807-25; PMID:12676168; http://dx.doi.org/10.1016/S1357-2725(02)00311-4.
13. M.Paul, A.Poyan Mehr, R.Kreutz. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86:747-803; PMID:16816138; http://dx.doi.org/10.1152/physrev.00036.2005.
14. L.Yvan-Charvet, A.Quignard-Boulange. Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int 2011; 79:162-8; PMID:20944545; http://dx.doi.org/10.1038/ki.2010.391.
15. B.H.Jones, M.K.Standridge, N.Moustaid. Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 1997; 138:1512-9; PMID:9075710.
16. M.Boschmann, J.Ringel, S.Klaus, A.M.Sharma. Metabolic and hemodynamic response of adipose tissue to angiotensin II. Obes Res 2001; 9:486-91; PMID:11500529; http://dx.doi.org/10.1038/oby.2001.63.
17. S.Yamamoto, P.G.Yancey, Y.Zuo, L.J.Ma, R.Kaseda, A.B.Fogo, I.Ichikawa, M.F.Linton, S.Fazio, V.Kon. Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arterioscler Thromb Vasc Biol 2011; 31:2856-64; PMID:21979434; http://dx.doi.org/10.1161/ATVBAHA.111.237198.
18. J.D.Zhang, M.B.Patel, R.Griffiths, P.C.Dolber, P.Ruiz, M.A.Sparks, J.Stegbauer, H.Jin, J.A.Gomez, A.F.Buckley, et al. Type 1 angiotensin receptors on macrophages ameliorate IL-1 receptor-mediated kidney fibrosis. J Clin Invest 2014; 124:2198-203; PMID:24743144; http://dx.doi.org/10.1172/JCI61368.
19. L.L.Souza, C.M.Costa-Neto. Angiotensin-(1–7) decreases LPS-induced inflammatory response in macrophages. J Cell Physiol 2012; 227:2117-22; PMID:21769868; http://dx.doi.org/10.1002/jcp.22940.
20. S.E.Thatcher, M.Gupte, N.Hatch, L.A.Cassis. Deficiency of ACE2 in Bone-Marrow-Derived cells increases expression of TNF-α in adipose stromal cells and augments glucose intolerance in obese C57BL/6 mice. Int J Hypertens 2012; 2012:762094; PMID:22518292; http://dx.doi.org/10.1155/2012/762094.
21. V.B.Patel, S.Bodiga, R.Basu, S.K.Das, W.Wang, Z.Wang, J.Lo, M.B.Grant, J.Zhong, Z.Kassiri, et al. Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction:a critical role of the angiotensin II/AT1 receptor axis. Circ Res 2012; 110:1322-35; PMID:22474255; http://dx.doi.org/10.1161/CIRCRESAHA.112.268029.
22. V.B.Patel, S.Bodiga, D.Fan, S.K.Das, Z.Wang, W.Wang, R.Basu, J.Zhong, Z.Kassiri, G.Y.Oudit. Cardioprotective Effects Mediated by Angiotensin II Type 1 Receptor Blockade and Enhancing Angiotensin 1–7 in Experimental Heart Failure in Angiotensin-Converting Enzyme 2-Null Mice. Hypertension 2012; 59:1195-203; PMID:22508831; http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.191650.
23. V.B.Patel, N.Parajuli, G.Y.Oudit. Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. Clin Sci (Lond) 2014; 126:471-82; PMID:24329564; http://dx.doi.org/10.1042/CS20130344.
24. V.B.Patel, A.Takawale, T.Ramprasath, S.K.Das, R.Basu, M.B.Grant, D.A.Hall, Z.Kassiri, G.Y.Oudit. Antagonism of angiotensin 1–7 prevents the therapeutic effects of recombinant human ACE2. J Mol Med (Berl) 2015; 93(9):1003-13.
25. V.B.Patel, J.C.Zhong, D.Fan, R.Basu, J.S.Morton, N.Parajuli, M.S.McMurtry, S.T.Davidge, Z.Kassiri, G.Y.Oudit. Angiotensin-converting enzyme 2 is a critical determinant of angiotensin II-induced loss of vascular smooth muscle cells and adverse vascular remodeling. Hypertension 2014; 64:157-64; PMID:24799609; http://dx.doi.org/10.1161/HYPERTENSIONAHA.114.03388.
26. W.Wang, V.B.Patel, N.Parajuli, D.Fan, R.Basu, Z.Wang, T.Ramprasath, Z.Kassiri, J.M.Penninger, G.Y.Oudit. Heterozygote loss of ACE2 is sufficient to increase the susceptibility to heart disease. J Mol Med (Berl) 2014; 92:847-58; PMID:24728465; http://dx.doi.org/10.1007/s00109-014-1149-y.
27. V.B.Patel, J.Mori, B.A.McLean, R.Basu, S.K.Das, T.Ramprasath, N.Parajuli, J.M.Penninger, M.B.Grant, G.D.Lopaschuk, et al. ACE2 deficiency worsens epicardial adipose tissue inflammation and cardiac dysfunction in response to diet-induced obesity. Diabetes 2015; 65(1):85-95; http://dx.doi.org/10.2337/db15-0399.
28. S.Fujisaka, I.Usui, A.Bukhari, M.Ikutani, T.Oya, Y.Kanatani, K.Tsuneyama, Y.Nagai, K.Takatsu, M.Urakaze, et al. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 2009; 58:2574-82; PMID:19690061; http://dx.doi.org/10.2337/db08-1475.
29. S.Cherian, G.D.Lopaschuk, E.Carvalho. Cellular cross-talk between epicardial adipose tissue and myocardium in relation to the pathogenesis of cardiovascular disease. Am J Physiol Endocrinol Metab 2012; 303:E937-49; PMID:22895783; http://dx.doi.org/10.1152/ajpendo.00061.2012.
30. L.F.Van Gaal, I.L.Mertens, C.E.De Block. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444:875-80; PMID:17167476; http://dx.doi.org/10.1038/nature05487.
31. R.Fontes-Carvalho, M.Fontes-Oliveira, F.Sampaio, J.Mancio, N.Bettencourt, M.Teixeira, F.Rocha Gonçalves, V.Gama, A.Leite-Moreira. Influence of epicardial and visceral fat on left ventricular diastolic and systolic functions in patients after myocardial infarction. Am J Cardiol 2014; 114:1663-9; PMID:25306552; http://dx.doi.org/10.1016/j.amjcard.2014.08.037.
32. T.P.Fitzgibbons, M.P.Czech. Epicardial and perivascular adipose tissues and their influence on cardiovascular disease:basic mechanisms and clinical associations. J Am Heart Assoc 2014; 3:e000582; PMID:24595191; http://dx.doi.org/10.1161/JAHA.113.000582.
33. A.E.Loot, A.J.Roks, R.H.Henning, R.A.Tio, A.J.Suurmeijer, F.Boomsma, W.H.van Gilst. Angiotensin-(1–7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002; 105:1548-50; PMID:11927520; http://dx.doi.org/10.1161/01.CIR.0000013847.07035.B9.
34. R.A.Santos, A.C.Simoes e Silva, C.Maric, D.M.Silva, R.P.Machado, I.de Buhr, S.Heringer-Walther, S.V.Pinheiro, M.T.Lopes, M.Bader, et al. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 2003; 100:8258-63; PMID:12829792; http://dx.doi.org/10.1073/pnas.1432869100.
35. C.Skurk, F.Wittchen, L.Suckau, H.Witt, M.Noutsias, H.Fechner, H.P.Schultheiss, W.Poller. Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy. Eur Heart J 2008; 29:1168-80; PMID:18390538; http://dx.doi.org/10.1093/eurheartj/ehn136.
36. K.Dadson, Y.Liu, G.Sweeney. Adiponectin action:a combination of endocrine and autocrine/paracrine effects. Front Endocrinol 2011; 2:62; PMID:22649379; http://dx.doi.org/10.3389/fendo.2011.00062.
37. J.Mori, V.B.Patel, T.Ramprasath, O.A.Alrob, J.DesAulniers, J.W.Scholey, G.D.Lopaschuk, G.Y.Oudit. Angiotensin 1–7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. Am J Physiol Renal Physiol 2014; 306:F812-21; PMID:24553436; http://dx.doi.org/10.1152/ajprenal.00655.2013.
38. G.Iacobellis, D.Corradi, A.M.Sharma. Epicardial adipose tissue:anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2005; 2:536-43; PMID:16186852; http://dx.doi.org/10.1038/ncpcardio0319.